Friday, January 22, 2010

Market Outlook 22nd Jan 2010

Strong & Weak  futures  
This is list of 10 strong futures: 
Sun TV, GTL Infra, Finance Tech, Chambal Fert, Pantaloon Retail, Dish TV, Federal Bank, Nagarjuna Fertil, Triveni & DCB.
And this is list of 10 Weak futures:
LITL, Pir Health, Hind Petro, LT, Balrampur Chini, Orchid Chem, BPCL, Bajaj Hind, Praj Industry & HDFC.
 Nifty is in Down trend  
 
 

NIFTY FUTURES (F & O):  

Selling may continue up to 5063 level for time being.

 

Hurdles at 5095 & 5116 levels. Above these levels, expect short covering up to 5167-5169 zone and thereafter expect a jump up to 5217-5219 zone by non-stop.

 

 Sell if touches 5301-5303 zone. Stop Loss at 5351-5353 zone.  

 

On Negative Side, break below 5010-5012 zone can create panic up to 4960-4962 zone by non-stop. If breaks & sustains this zone then down trend may continue and have caution.

 

Short-Term Investors:

 Bullish Trend. Stop Loss at 5155.00.

 Up Side Target at 5339.00.

  

Now Stop Loss triggered. Down Target at 5063.00 level. 3 closes below 5063.00 level it can

 

tumble up to 4971.00 level by non-stop.

 

Equity:

 GTL LTD (NSE Cash)

 Explosive. Do remember that, down side risk up to 404 level is possible. Buy at around this level with a Stop Loss of 403 level.

 

Rally up to 413-415 zone may be possible & thereafter expect a jump up to 422 level also possible.

 

 SRF LTD (NSE Cash)

 Explosive. Do remember that, down side risk up to 199 level is possible. Buy at around this level with a Stop Loss of 197 level.

 Rally up to 203-205 zone may be possible.

  

Cross above 208 level, this scrip will explode up to 210-212 zone by non-stop.

 

RELIANCE INDS (NSE Cash)

 Weak. Do remember that, if crosses & sustains above 1065 level, then it can zoom up to 1075 level by non-stop. Sell at around this level with a Stop Loss of 1077 level.

  

Fall up to 1038 & 1043 levels may be possible.

 Break below 1027 level, expect panic up to 1021-1023 zone by non-stop.

 

 RASHTRIYA CHEM (NSE Cash): 

 Bulls may get trapped at higher levels during intra-day trades today. Expect Positive News within a Week.

  

JAI CORPORATION (NSE Cash): 

 

Bulls may get trapped at higher levels during intra-day trades today. Expect Negative News within a Month.

  

JET AIRWAYS (NSE Cash):

 Bulls may get trapped at higher levels during intra-day trades today. Expect Negative News within a Week.

  

AXIS BANK (NSE Cash): 

 Bears may get trapped at lower levels during intra-day trades today. Expect Positive News within a Month.

  

LANCO INFRATECH (NSE Cash): 

 Bears may get trapped at lower levels during intra-day trades today. Expect Positive News within a Week.

  

OPTIONS (NSE):

NIFTY 5100 PUT OPTION

 Today's trend is sideways pattern with Positive bias. If rally continues, then it can zoom up to 84 level by non-stop.

 

On Negative side, if profit booking starts then slide may continue up to 21 level by non-stop. Too risky.

 

TATA STEEL 640 PUT OPTION

 Today's trend is sideways pattern with Positive bias. If rally continues, then it can zoom up to 18 level by non-stop.

  

On Negative side, if profit booking starts then slide may continue up to 8 level by non-stop.

 

STOCK FUTURES (NSE):

DR REDDY FUTURES 

 Weak. Do remember that, if crosses & sustains above 1133 & 1145 levels, then it can zoom up to 1156 level by non-stop. Sell at around this level with a Stop Loss of 1165 level.

 

Fall up to 1111 level may be possible & thereafter fall may continue up to 1096 level (or) even up to 1083-1085 zone by non-stop.

  

Break below 1073 level, expect panic up to 1064 level by non-stop.

 

LARSEN & TOUBRO FUTURES

 Stock may crash up to 1395 level today & may touch 1356 level on (or) before expiry.

 

On Positive side, short covering may be restricted up to 1635 level today & 1674 level on (or) before expiry.

 

INVESTMENT BUY:

 PATEL AIRTEMP (BSE Code:517417)

 

1 Week Target at 149.05.

 

 Stop Loss at 111.95.

  

INVESTMENT VIEW

Bilcare: Global Clinical Supplies

  

Bilcare GCS serves the global pharmaceutical and bio-pharmaceutical industries with clinical trial materials support, services and complete project management.

  

With best-in-class manufacturing plants and facilities on three continents, Bilcare GCS delivers end-to-end solutions that support a client's drug through the entire clinical trial life cycle.

 

 

 

It provides services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling to IVRS, QP services, controlled-temperature (cold chain) CTM storage, worldwide distribution and returns and destructions accountability.

 

 

Facilities

 

 

Bilcare GCS supports customers from an integrated global network of manufacturing sites and expanded distribution, depots and warehousing facilities - with major operations in the Americas, Europe and Asia Pacific. 

 

 

Bilcare GCS, Americas

 

 

The company's U.S. operation is FDA-registered and DEA-licensed for controlled substances Schedule I-V (importer, exporter, distributor, manufacturing and analytical laboratory).

 

 

 

Enhancements to the U.S. facility include 26 state-of-the-art packaging rooms, new high-speed blistering technology, upgraded large-scale bottling line and tripling the capacity of the facility's ambient storage capacity. Expanded pre-clinical and early-stage development capabilities include upgraded fluid bed granulation and capsule-filling technology. 

 

 

Bilcare GCS, Europe

 

 

Bilcare GCS Europe operates with an MHRA-manufacturers license located in Wales, UK. This facility conforms to the EU clinical trials directives for addressing the complete needs of phase I to IV clinical trials.

 

 

 

The company holds MHRA manufacture and assembly license Specials, MHRA wholesale dealers import license, Home Office CD license and plant master file registration with US FDA.

 

 

 

Capital investments include a new high-speed blistering line, expanded cold chain and controlled drug storage, and expansion to 13 primary and secondary packaging rooms. 

 

 

Bilcare GCS, Asia Pacific

 

 

Bilcare GCS, Asia Pacific has a state-of-the-art facility in Pune, India. The Pune facility has expanded its primary and secondary packaging and storage capacity to include manufacture, packaging and distribution of CTM.

 

 

Services

 

 

Bilcare GCS has core expertise in:

 

Clinical Supplies Project Management

 

Formulation development

 

Analytical & research services

 

Clinical manufacturing, packaging & labeling

 

IVRS/IWRS

 

Global logistics & distribution

 

Depot alliance

 

Reconciliation & destruction services

 

QP services

 

Returns management & archiving samples & record.

 

 

Technicals for Today:

 

 

Sideways pattern with negative bias. 

 

 

If down trend continues, then it can tumble up to 486 level.

 

 

If start rallies, then Short covering may be restricted up to 546 level.

 

 

 

 

(Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints.

 

 

Nothing in this article is, or should be construed as, investment advice.) 


 
SPOT INDEX LEVELS
NSE Nifty Index   5094.15 ( -2.44 %) -127.55       
  1 2 3
Resistance 5251.80 5281.90   5307.10  
Support 5196.50 5171.30 5141.20

BSE Sensex  17051.14 ( -2.42 %) -423.35     
  1 2 3
Resistance 17568.37 17662.25 17733.91
Support 17402.83 17331.17 17237.29
FII DATA
FII trading activity on NSE and BSE in Capital Market Segment(In Rs. Crores)
Category Date Buy Value Sell Value Net Value
FII 21-Jan-2010 2673.32 3527.07 -853.75
DII trading activity on NSE and BSE in Capital Market Segment(In Rs. Crores)
Category Date Buy Value Sell Value Net Value
DII 21-Jan-2010 1810.6 1579.24 231.36


--
Arvind Parekh
+ 91 98432 32381